ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911

Its studies are led by Mabwell (Shanghai) Bioscience.

Furthest: phase 2, since Sep 24, 20252 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mabwell (Shanghai) Bioscience22 open or runningphase 2since Sep 24, 2025Sep 24, 2025Jul 2027phase 2 · NCT07216560

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 24, 2025First study: phase 2 study in GI CancersFirst studyNCT07216560 · 200 planned · United States
  2. Nov 16, 2025Phase 2 study in Solid TumorsNCT07265622 · 200 planned · China

Ahead

  1. Jul 2027Primary completion: phase 2 study in Solid TumorsNCT07265622
  2. Jul 2027Primary completion: phase 2 study in GI CancersNCT07216560

TargetBeta

CDH17 →read by rule
“An antibody-drug conjugate (ADC) composed of Mab0727, a monoclonal antibody targeting the tumor-associated antigen (TAA) cadherin-17 (CDH17) ”NCIt, by rule

Other programs on CDH17

ProgramCompanyFurthest phaseStudies
Anti-CDH17 Antibody-drug Conjugate HS-20110Hansoh Pharmaceutical Groupphase 22
AMT-676rulemultitude-therapeutics-incphase 22
Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324ruledualitybio-incphase 21
LM-350Sino Biopharmaceuticalphase 21
Anti-CDH17 Antibody-drug Conjugate YL217ruleMediLink Therapeutics (Suzhou)phase 11
Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217rulearrivent-biopharma-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07265622Solid Tumors · China2RecruitingJul 2027200
NCT07216560GI Cancers · United States2RecruitingJul 2027200

How it is read

Names in the registry

  • “7MW4911”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.